Haemophilus B and hepatitis B vaccine
| Combination of | |
|---|---|
| Hib vaccine | Vaccine |
| Hepatitis B vaccine | Vaccine |
| Clinical data | |
| Trade names | Comvax |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Intramuscular injection |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Haemophilus B and hepatitis B vaccine is a combination vaccine whose generic name is Haemophilus b conjugate and hepatitis B recombinant vaccine.[1][2] It protects against the infectious diseases Haemophilus influenzae type B and hepatitis B.[2]
A branded formulation, Comvax, was marketed in the US by Merck.[3][4] It was discontinued in 2014.[5]
References
- ↑ "Comvax". Drugs.com. Retrieved 15 July 2018.
- 1 2
- ↑ Centers for Disease Control and Prevention (February 1997). "FDA approval for infants of a Haemophilus influenzae type b conjugate and hepatitis B (recombinant) combined vaccine" (PDF). MMWR Morb. Mortal. Wkly. Rep. 46 (5): 107–9. PMID 9045037.
- ↑ "Comvax package insert" (PDF). Retrieved 15 July 2018.
- ↑ Zarei AE, Almehdar HA, Redwan EM (2016). "Hib Vaccines: Past, Present, and Future Perspectives". Journal of Immunology Research. 2016: 7203587. doi:10.1155/2016/7203587. PMC 4745871. PMID 26904695.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.